Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Cellular & molecular immunology - 20(2023), 4 vom: 03. Apr., Seite 419-422 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoffmann, Markus [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 04.04.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41423-023-00988-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353750824 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353750824 | ||
| 003 | DE-627 | ||
| 005 | 20231226060732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41423-023-00988-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353750824 | ||
| 035 | |a (NLM)36869193 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoffmann, Markus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Arora, Prerna |e verfasserin |4 aut | |
| 700 | 1 | |a Nehlmeier, Inga |e verfasserin |4 aut | |
| 700 | 1 | |a Kempf, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Cossmann, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Sebastian R |e verfasserin |4 aut | |
| 700 | 1 | |a Morillas Ramos, Gema |e verfasserin |4 aut | |
| 700 | 1 | |a Manthey, Luis A |e verfasserin |4 aut | |
| 700 | 1 | |a Jäck, Hans-Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Behrens, Georg M N |e verfasserin |4 aut | |
| 700 | 1 | |a Pöhlmann, Stefan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular & molecular immunology |d 2004 |g 20(2023), 4 vom: 03. Apr., Seite 419-422 |w (DE-627)NLM158038010 |x 2042-0226 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:4 |g day:03 |g month:04 |g pages:419-422 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41423-023-00988-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 4 |b 03 |c 04 |h 419-422 | ||